December 10, 2022

Only three major adverse effects of the Covid-19 vaccines were reported so far among the close to 30,000 individuals who were inoculated in the Cordillera.

Department of Health-Cordillera Nurse Geeney Anne Austria said three vaccinees have developed allergic reactions after receiving their Covid-19 shots and have since recovered.

Austria said those who developed minor adverse effects following immunization (AEFI) were also managed well and have since recovered.

The DOH Regional Epidemiology and Surveillance Unit continues to monitor all reactions from individuals who received their shots as a way of ensuring vaccine safety.

Austria said 1,399 of the 1,402 who reported AEFI experienced minor reactions such as fever, headaches, and pain in the arm, which she said are the usual reactions of people who received a vaccine.

She asked those who received their shots to report any side effects to concerned offices and asked those who have doubts on the vaccine to consult only the health experts.

As of April 13, a total of 29,875 individuals under Priority A1 or the frontline health workers and Priority A3 or those with controlled comorbidities have been inoculated.

Of those vaccinated, 6,836 have completed their second dose, according to DOH-Cordillera Assistant Director Amelita Pangilinan.

The vaccinees who completed their second dose were inoculated with Sinovac.

Pangilinan said the second dose for those vaccinated with the AstraZeneca is yet to arrive.

A total of 10,313 individuals in the region received their first shot of AstraZeneca.

The government is expecting the arrival of the AstraZeneca shots this month for the second dose of those who had their first shot when the vaccine was rolled out in March.

Those vaccinated with Sinovac are assured of the doses for their second shots, except those who were administered the AstraZeneca as the government has decided to administer the vaccine as first doses to cover more eligible vaccinees.

Earlier, the Food and Drugs Administration has asked the DOH to suspend the use of AstraZeneca following reports of rare cases of blood clots.

FDA Director-General Rolando Domingo has said the recommendation to suspend the administration of Astrazeneca was not because of its inefficiency, but out of caution and to allow for more evidence if the vaccine was the sole cause of the blood clots as reported in Europe.

Also, in earlier statements, Domingo said so far, there are no reports of blood clots from those who received their Astrazeneca shots. – Jane B. Cadalig